Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study)

Abstract

65 patients with nonalcoholic fatty liver disease (NAFLD) were included in open-label observative prospective cohort study. Mean age was 54.8 ± 10.5 y. o. All patients were treated with metformin before and during the study. All patients were treated by GLP-1 receptor agonist dulaglutide subcutaneously weekly 26 weeks. Patients of group with type 2 diabetes were treated with dulaglutide 0.75 mg weekly 2 weeks, than 1.5 weekly 24 weeks. Patients of group without diabetes were treated by dulaglutide 0.75 mg weekly 4 weeks, than 1.5 weekly 22 weeks. Both groups of patients were demonstrated significant reduce of body weight, BMI, waist circumference, glucose, HbA1c, insulin resistance indexes, transaminases and gamma-glutamyltranspeptidase activity. Fatty liver index and liver stiff ness also decreased after treatment. We can conclude that dulaglutide treatment in NAFLD patients decreases body wieight, improves glucose and lipid metabolism and decreases inflammatory activity of steatohepatitis.

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

“…В последовавшем за этим РКИ 2 фазы LEAN (52 больных с СД2 и гистологически подтвержденным НАСГ) лираглутид продемонстрировал существенное уменьшение морфологических проявлений НАСГ без увеличения выраженности фиброза печени [16]. Согласно проведенному исследованию с еще одним представителем данного класса терапия дулаглутидом у пациентов с НАЖБП обусловливает значимое снижение массы тела, улучшение показателей углеводного и липидного обмена, а также уменьшение биохимических маркеров активности стеатогепатита [39]. В настоящее время изучаются возможности применения при СД 2 (в т.ч.…”